



## Drug Coverage Policy

Effective Date .....05/01/2026  
Coverage Policy Number.....PSM006  
Policy Title.....Orencia Intravenous  
Preferred Specialty Management Policy  
for Standard/Performance,  
Value/Advantage, Total Savings

# Inflammatory Conditions – Orencia Intravenous Preferred Specialty Management Policy for Employer Plans: Standard/Performance, Value/Advantage, Total Savings Prescription Drug Lists

- Orencia® (abatacept intravenous infusion - Bristol-Myers Squibb)

---

### **INSTRUCTIONS FOR USE**

*The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment where appropriate and have discretion in making individual coverage determinations. Where coverage for care or services does not depend on specific circumstances, reimbursement will only be provided if a requested service(s) is submitted in accordance with the relevant criteria outlined in the applicable Coverage Policy, including covered diagnosis and/or procedure code(s). Reimbursement is not allowed for services when billed for conditions or diagnoses that are not covered under this Coverage Policy (see "Coding Information" below). When billing, providers must use the most appropriate codes as of the effective date of the submission. Claims submitted*

for services that are not accompanied by covered code(s) under the applicable Coverage Policy will be denied as not covered. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

## OVERVIEW

Several products are available for use in inflammatory conditions such as rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis.<sup>1-4</sup> This policy involves the use of Orencia intravenous infusion.

## Coverage Policy

### POLICY STATEMENT

For all medications, this program requires the patient to meet the respective standard *Prior Authorization Policy* criteria. Additionally, this program requires trial(s) of the Preferred Product(s) according to the table below, when clinically appropriate, prior to the approval of the Non-Preferred Products. There are also situations when trials of Non-Preferred Products will be considered; see criteria below. Other details of the program are as follows:

- **Continuation of Therapy:** Approval for a patient continuing therapy with a Non-Preferred subcutaneous or oral Product must be supported with verification, noted in the criteria as either **[verification in prescription claims history required]** or, if not available, as **[verification by prescriber required]**.
  - If the patient has at least 130 days of prescription claims history on file, claims history must support that the patient has received the Non-Preferred Product for the specified period of time (90 or 120 days) within a 130-day look-back period; OR
  - When 130 days of the patient’s prescription claim history file is unavailable for verification, the prescriber must verify that the patient has been receiving the Non-Preferred Product for a specified period of time (90 or 120 days), AND that the patient has been receiving the Non-Preferred Product via paid claims (e.g., patient has not been receiving samples or coupons or other types of waivers in order to obtain access to the Non-Preferred Product).
  - For a patient continuing therapy, other conditions may also apply. Refer to criteria below.
- **Approval Duration:** All approvals for continuation of therapy for Preferred and Non-Preferred Products are provided for 1 year unless noted otherwise below. In cases where the initial approval is authorized in months, 1 month is equal to 30 days.

**Documentation:** When documentation is required, the prescriber must provide written documentation supporting the trials of these other Products, noted in the criteria as **[documentation required]**. Documentation may include, but is not limited to, chart notes, prescription claims records, and/or prescription receipts. All documentation must include patient-specific identifying information.

### Preferred and Non-Preferred Products.

	Rheumatology		
	Rheumatoid Arthritis	Juvenile Idiopathic Arthritis	Psoriatic Arthritis
<b>Step 1 Preferred</b>	<ul style="list-style-type: none"> <li>• Enbrel</li> <li>• Adalimumab</li> </ul> <b>Products –</b>	<ul style="list-style-type: none"> <li>• Enbrel</li> <li>• Adalimumab</li> </ul> <b>Products –</b>	<ul style="list-style-type: none"> <li>• Enbrel</li> <li>• Adalimumab</li> </ul> <b>Products –</b>

	Cyltezo/ adalimumab- adbm, Simlandi/ adalimumab- ryvk (-ryvk NDCs starting with 82009)	Cyltezo/ adalimumab- adbm, Simlandi/ adalimumab- ryvk (-ryvk NDCs starting with 82009)	Cyltezo/ adalimumab-adbm, Simlandi/ adalimumab-ryvk (-ryvk NDCs starting with 82009) • <b>Otezla/Otezla XR</b> • <b>Skyrizi SC</b> • <b>Sotyktu</b> • <b>Ustekinumab SC</b> <b>Products –</b> Imuldosa SC (NDCs starting with 69448), Selarsdi SC, ustekinumab- ttwe SC, Yesintek SC • <b>Taltz</b> • <b>Tremfya</b>
<b>Step 2a</b> <b>Non-Preferred</b> (directed to <b>ONE</b> Step 1 Product)	<ul style="list-style-type: none"> <li>• <b>Tocilizumab SC Products –</b> Actemra SC, Avtozma SC, Tyenne SC <i>Directed to adalimumab specifically.</i></li> <li>• <b>Rinvoq</b></li> <li>• <b>Xeljanz tablets/ Xeljanz XR tablets</b></li> </ul>	<ul style="list-style-type: none"> <li>• <b>Tocilizumab SC Products -</b> Actemra SC, Avtozma SC, Tyenne SC <i>Directed to adalimumab specifically. JIA Step SC is for PJIA.</i></li> <li>• <b>Rinvoq/Rinvoq LQ</b></li> <li>• <b>Xeljanz tablets/ Xeljanz oral solution</b></li> </ul>	<ul style="list-style-type: none"> <li>• <b>Rinvoq/ Rinvoq LQ</b> <i>Directed specifically to Enbrel or adalimumab.</i></li> <li>• <b>Xeljanz (tablets or oral solution)/Xeljanz XR tablets</b> <i>Directed specifically to Enbrel or adalimumab.</i></li> </ul>
<b>Step 2b</b> <b>Non-Preferred</b> (directed to <b>ONE</b> Step 1 Product)			• <b>Bimzelx</b>
<b>Step 3</b> <b>Non-Preferred</b> (directed to <b>TWO</b> Step 1 or 2a Products) <b>[documentation required]*</b>	• <b>Orencia Intravenous</b>	• <b>Orencia Intravenous</b>	• <b>Orencia Intravenous</b>

For Non-Preferred Adalimumab Products, refer to the *Inflammatory Conditions – Adalimumab Products Preferred Specialty Management Policy (PSM013)*; For Non-Preferred Ustekinumab Products, refer to the *Inflammatory Conditions – Ustekinumab Subcutaneous Products Preferred Specialty Management Policy for Standard/Performance, Value/Advantage, and Total Savings Prescription Drug Lists (PSM021)*; A trial of more than one adalimumab product counts as ONE Preferred Product; A trial of more than one ustekinumab product counts as ONE Preferred Product. \* The prescriber must provide written documentation supporting the trial of Preferred Products, noted in the criteria as **[documentation required]**.

Documentation may include, but is not limited to, chart notes, prescription claims records, and/or prescription receipts. All documentation must include patient-specific identifying information.

**Orencia intravenous is considered medically necessary when the following non-preferred product exception criteria is met. Any other exception is considered not medically necessary.**

**NON-PREFERRED PRODUCT EXCEPTION CRITERIA**

Non-Preferred Products	Exception Criteria
<p><b>Orencia Intravenous</b></p>	<p><b>1. Rheumatoid Arthritis (RA) - Initial Therapy.</b></p> <p><b>A)</b> Approve for 6 months if patient meets BOTH of the following (i and ii)</p> <ul style="list-style-type: none"> <li><b>i.</b> Patient meets the standard <i>Inflammatory Conditions – Orencia Intravenous Prior Authorization Policy</i> criteria; AND</li> <li><b>ii.</b> Patient meets ONE of the following (a or b):           <ul style="list-style-type: none"> <li><b>a)</b> Patient has tried two of a tocilizumab subcutaneous product, Enbrel, an adalimumab product, Rinvoq, or Xeljanz/XR [<b>documentation required</b>]; OR                Note: Examples of tocilizumab subcutaneous products include Actemra subcutaneous, Avtozma subcutaneous, and Tyenne subcutaneous. A trial of multiple tocilizumab products counts as <b>ONE</b> product. Examples of adalimumab products include Humira, Abrilada, adalimumab-aacf, adalimumab-adaz, adalimumab-adbm, adalimumab-fkjp, adalimumab-aaty, adalimumab-ryvk, Simlandi, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yuflyma, and Yusimry. A trial of multiple adalimumab products counts as <b>ONE</b> product. A trial of either or both Xeljanz products (Xeljanz and Xeljanz XR) collectively counts as <b>ONE</b> product. A trial of tocilizumab intravenous (Actemra intravenous, biosimilar), Cimzia, an infliximab product (e.g., Remicade, biosimilars), Kevzara, or Simponi (Aria or subcutaneous) also counts [<b>documentation required</b>].</li> <li><b>b)</b> According to the prescriber, the patient has heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, OR a demyelinating disorder.</li> </ul> </li> </ul> <p><b>B)</b> If the patient has met criterion 1Ai (the standard <i>Inflammatory Conditions – Orencia Intravenous Prior Authorization Policy</i> criteria), but criterion 1Aii is not met: a request for a Step 1 or 2a Product may be reviewed (<u>Actemra subcutaneous, Avtozma subcutaneous, Tyenne subcutaneous, Enbrel, adalimumab-adbm, Cyltezo, adalimumab-ryvk [NDCs starting with 82009], Simlandi, Rinvoq, Xeljanz tablets, or Xeljanz XR</u>) using the respective standard <i>Inflammatory Conditions Prior Authorization Policy</i> criteria.</p> <p><b>2. Juvenile Idiopathic Arthritis – Initial Therapy.</b></p>

- A)** Approve for 6 months if patient meets BOTH of the following (i and ii):
- i.** Patient meets the standard *Inflammatory Conditions – Orencia Intravenous Prior Authorization Policy* criteria; AND
  - ii.** Patient meets ONE of the following (a or b):
    - a)** Patient has tried TWO of a tocilizumab subcutaneous product, Enbrel, an adalimumab product, Rinvoq/Rinvoq LQ, or Xeljanz **[documentation required]**; OR  
Note: Examples of tocilizumab subcutaneous products include Actemra subcutaneous, Avtozma subcutaneous, and Tyenne subcutaneous. A trial of multiple tocilizumab products counts as **ONE** product. Examples of adalimumab products include Humira, Abrilada, adalimumab-aacf, adalimumab-adaz, adalimumab-adbm, adalimumab-fkjp, adalimumab-aaty, adalimumab-ryvk, Simlandi, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yuflyma, and Yusimry. A trial of multiple adalimumab products counts as **ONE** product. A trial of either or both Xeljanz products (Xeljanz tablets and Xeljanz oral solution) collectively counts as **ONE** product. A trial of either or both Rinvoq products (Rinvoq and Rinvoq LQ) collectively counts as **ONE** product. A trial of tocilizumab intravenous (Actemra intravenous, biosimilar), Kevzara, Orencia subcutaneous, Cimzia, an infliximab product (e.g., Remicade, biosimilar), or Simponi Aria also counts **[documentation required]**.
    - b)** According to the prescriber, the patient has heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, OR a demyelinating disorder.
- B)** If the patient has met criterion 2Ai (the standard *Inflammatory Conditions – Orencia Intravenous Prior Authorization Policy* criteria), but criterion 2Aii is not met, a request for a Step 1 or 2a Product may be reviewed (Actemra subcutaneous, Avtozma subcutaneous, Tyenne subcutaneous, Enbrel, adalimumab-adbm, Cyltezo, adalimumab-ryvk [NDCs starting with 82009], Simlandi, Rinvoq, Rinvoq LQ, Xeljanz tablets, or Xeljanz oral solution) using the respective standard *Inflammatory Conditions – Prior Authorization Policy* criteria.

**3. Psoriatic Arthritis, Initial Therapy.**

- A)** Approve for 6 months if patient meets BOTH of the following (i and ii):
- i.** Patient meets the standard *Inflammatory Conditions – Orencia Intravenous Prior Authorization Policy* criteria; AND
  - ii.** Patient meets ONE of the following (a or b):
    - a)** Patient has tried TWO of Enbrel, an adalimumab product, Otezla/Otezla XR, Rinvoq/Rinvoq LQ, Skyrizi subcutaneous, Sotyktu, an ustekinumab subcutaneous product, Taltz, Tremfya, or Xeljanz/XR **[documentation required]**; OR  
Note: Examples of adalimumab products include Humira, Abrilada, adalimumab-aacf, adalimumab-adaz, adalimumab-adbm, adalimumab-fkjp, adalimumab-aaty,

adalimumab-ryvk, Simlandi, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yuflyma, and Yusimry. Examples of ustekinumab products include Stelara/ustekinumab, Imuldosa, Otulfi, Pyzchiva, ustekinumab-ttwe, Selarsdi, ustekinumab-aekn, Starjemza, Steqeyma, Wezlana, and Yesintek. A trial of multiple adalimumab products counts as **ONE** product. A trial of multiple ustekinumab products counts as **ONE** product. A trial of either or both Otezla products (Otezla and Otezla XR) collectively counts as **ONE** product. A trial of either or both Xeljanz products (Xeljanz and Xeljanz XR) collectively counts as **ONE** product. A trial of either or both Rinvoq products (Rinvoq and Rinvoq LQ) collectively counts as **ONE** product. A trial of Cimzia, an infliximab product (e.g., Remicade, biosimilars), Simponi (Aria or subcutaneous), Cosentyx, or Bimzelx also counts [**documentation required**].

**b)** According to the prescriber, the patient has heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, OR a demyelinating disorder.

**B)** If the patient has met criterion 3Ai (the standard *Inflammatory Conditions – Orencia Intravenous Prior Authorization Policy* criteria), but criterion 3Aii is not met, a request for a Step 1 or Step 2a Product may be reviewed (Enbrel, adalimumab-adbm, Cyltezo, adalimumab-ryvk [NDCs starting with 82009], Simlandi, Otezla, Otezla XR, Rinvoq, Rinvoq LQ, Skyrizi subcutaneous (pen or syringe), Sotyktu, Imuldosa subcutaneous (NDCs starting with 69448), Selarsdi subcutaneous, ustekinumab-ttwe subcutaneous, Yesintek subcutaneous, Taltz, Tremfya, Xeljanz, or Xeljanz XR) using the respective standard *Inflammatory Conditions – Prior Authorization Policy* criteria.

**4. Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, or Psoriatic Arthritis – Patient is Currently Receiving Orencia (Subcutaneous or Intravenous).**

**A)** Approve for 1 year if the patient meets BOTH of the following (i and ii):

**i.** Patient meets the standard *Inflammatory Conditions – Orencia Intravenous Policy* criteria; AND

**ii.** Patient meets ONE of the following (a, b, c, d, e, or f):

**a)** Patient has Rheumatoid Arthritis and has tried TWO of a tocilizumab subcutaneous product, Enbrel, an adalimumab product, Rinvoq, or Xeljanz/XR [**documentation required**]; OR

Note: Examples of tocilizumab subcutaneous products include Actemra subcutaneous, Avtozma subcutaneous, and Tyenne subcutaneous. A trial of multiple tocilizumab products counts as **ONE** product. Examples of adalimumab products include Humira, Abrilada, adalimumab-aacf, adalimumab-adaz, adalimumab-adbm, adalimumab-fkjp, adalimumab-aaty, adalimumab-ryvk, Simlandi, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yuflyma, and Yusimry. A trial of multiple

	<p>adalimumab products counts as <b>ONE</b> product. A trial of either or both Xeljanz products (Xeljanz and Xeljanz XR) collectively counts as <b>ONE</b> product. A trial of tocilizumab intravenous (Actemra intravenous, biosimilar), Cimzia, an infliximab product (e.g., Remicade, biosimilars), Kevzara, or Simponi (Aria or subcutaneous) also counts <b>[documentation required]</b>.</p> <p><b>b)</b> Patient has <u>Juvenile Idiopathic Arthritis</u> and has tried TWO of a tocilizumab subcutaneous product, Enbrel, an adalimumab product, Rinvoq/Rinvoq LQ, and Xeljanz tablets or oral solution <b>[documentation required]</b>; OR <u>Note</u>: Examples of tocilizumab subcutaneous products include Actemra subcutaneous, Avtozma subcutaneous, and Tyenne subcutaneous. A trial of multiple tocilizumab products counts as <b>ONE</b> product. Examples of adalimumab products include Humira, Abrilada, adalimumab-aacf, adalimumab-adaz, adalimumab-adbm, adalimumab-fkjp, adalimumab-aaty, adalimumab-ryvk, Simlandi, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yuflyma, and Yusimry. A trial of multiple adalimumab products counts as <b>ONE</b> product. A trial of either or both Xeljanz products (Xeljanz tablets and Xeljanz oral solution) collectively counts as <b>ONE</b> product. A trial of either or both Rinvoq products (Rinvoq and Rinvoq LQ) collectively counts as <b>ONE</b> product. A trial of tocilizumab intravenous (Actemra intravenous, biosimilar), Kevzara, Orencia subcutaneous, Cimzia, an infliximab product (e.g., Remicade, biosimilars), or Simponi Aria also counts <b>[documentation required]</b>.</p> <p><b>c)</b> Patient has <u>Psoriatic Arthritis</u> AND has tried TWO of Enbrel, an adalimumab product, Otezla/Otezla XR, Rinvoq/Rinvoq LQ, Skyrizi subcutaneous, Sotyktu, an ustekinumab subcutaneous product, Taltz, Tremfya, or Xeljanz/XR <b>[documentation required]</b>; OR <u>Note</u>: Examples of adalimumab products include Humira, Abrilada, adalimumab-aacf, adalimumab-adaz, adalimumab-adbm, adalimumab-fkjp, adalimumab-aaty, adalimumab-ryvk, Simlandi, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yuflyma, and Yusimry. Examples of ustekinumab products include Stelara/ustekinumab, Imuldosa, Otulfi, Pyzchiva, ustekinumab-ttwe, Selarsdi, ustekinumab-aekn, Starjemza, Steqeyma, Wezlana, and Yesintek. A trial of multiple adalimumab products counts as <b>ONE</b> product. A trial of multiple ustekinumab products counts as <b>ONE</b> product. A trial of either or both Otezla products (Otezla and Otezla XR) collectively counts as <b>ONE</b> product. A trial of either or both Xeljanz products (Xeljanz and Xeljanz XR) collectively counts as <b>ONE</b> product. A trial of either or both Rinvoq products (Rinvoq and Rinvoq LQ) collectively counts as <b>ONE</b> product. A trial of Cimzia, an infliximab product (e.g., Remicade, biosimilars), Simponi (Aria or subcutaneous),</p>
--	--

Cosentyx, or Bimzelx also counts [**documentation required**].

- d) According to the prescriber, the patient has been established on Orencia intravenous for at least 90 days; OR
- e) According to the prescriber, the patient has heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, OR a demyelinating disorder; OR
- f) Patient has been established on Orencia subcutaneous for at least 90 days and prescription claims history indicates at least a 90-day supply of Orencia subcutaneous was dispensed within the past 130 days [**verification in prescription claims history required**], or if claims history is not available, according to the prescriber [**verification by prescriber required**].

Note: In cases when 130 days of the patient's prescription claim history file is unavailable to be verified, an exception to this requirement is allowed if the prescriber has verified that the patient has been receiving Orencia subcutaneous for at least 90 days AND the patient has been receiving Orencia subcutaneous via paid claims (e.g., patient has not been receiving samples or coupons or other types of waivers in order to obtain access to Orencia subcutaneous).

**B)** If the patient has met criterion 4Ai (the standard *Inflammatory Conditions – Orencia Intravenous Prior Authorization Policy* criteria), but criterion 4Aii is not met, a request for one of the following Products may be reviewed using the respective standard *Inflammatory Conditions Prior Authorization Policy* criteria.

- i. **Rheumatoid Arthritis:** Actemra subcutaneous, Avtozma subcutaneous, Tyenne subcutaneous, Enbrel, adalimumab-adbm, Cyltezo, adalimumab-ryvk (NDCs starting with 82009), Simlandi, Rinvoq, Xeljanz tablets, or Xeljanz XR.
- ii. **Juvenile Idiopathic Arthritis:** Actemra subcutaneous, Avtozma subcutaneous, Tyenne subcutaneous, Enbrel, adalimumab-adbm, Cyltezo, adalimumab-ryvk (NDCs starting with 82009), Simlandi, Rinvoq, Rinvoq LQ, Xeljanz tablets, or Xeljanz oral solution.
- iii. **Psoriatic Arthritis:** Enbrel, adalimumab-adbm, Cyltezo, adalimumab-ryvk (NDCs starting with 82009), Simlandi, Otezla, Otezla XR, Rinvoq, Rinvoq LQ, Skyrizi subcutaneous (pen or syringe), Sotyktu, Imuldosa subcutaneous (NDCs starting with 69448), Selarsdi subcutaneous, ustekinumab-ttwe subcutaneous, Yesintek subcutaneous, Taltz, Tremfya, Xeljanz, or Xeljanz XR.

**5. Other Conditions.** Approve Orencia intravenous (initial therapy for a duration as directed or 1 year for a patient continuing therapy) if the patient meets the standard *Inflammatory Conditions – Orencia Intravenous Prior Authorization Policy* criteria.

## References

1. Orenzia® intravenous infusion and subcutaneous injection [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; October 2024.

## Revision Details

Type of Revision	Summary of Changes	Date
New	New policy	11/01/2024
Selected Revision	<p><b>Humira:</b> Throughout the policy, NDCs starting with 00074 were removed from the Preferred Products. A previous trial of these NDCs counts towards a trial of an adalimumab product.</p> <p><b>Hyrimoz:</b> Throughout the policy, NDCs starting with 61314 were removed from the Preferred Products. A previous trial of these NDCs counts towards a trial of an adalimumab product.</p> <p>For <b>Juvenile Idiopathic Arthritis</b>, Cimzia was added as an agent that counts towards a trial of a Preferred Product.</p> <p>For <b>Polyarticular Juvenile Idiopathic Arthritis</b>, Cimzia was added as an agent that counts towards a trial of a Preferred Product.</p>	01/01/2025
Selected Revision	<p><b>For Psoriatic Arthritis:</b> Selarsdi subcutaneous, ustekinumab-ttwe subcutaneous, and Yesintek subcutaneous were added as Preferred ustekinumab subcutaneous products. A note was added indicating that a trial of multiple ustekinumab products counts as one product and examples of ustekinumab products were added including Stelara, Wezlana, Otufli, Pyzchiva, ustekinumab-ttwe, Selarsdi, Steqeyma, and Yesintek.</p>	04/15/2025
Selected Revision	<p><b>For All Conditions</b>, adalimumab-adaz was removed as a Preferred Product.</p> <p>Throughout the policy, the note was updated for the examples of ustekinumab products which include Stelara, ustekinumab (unbranded Stelara), Imuldosa, Otulfi, Pyzchiva, ustekinumab-ttwe, Selarsdi, ustekinumab-aekn, Starjemza, Steqeyma, Wezlana, and Yesintek.</p>	09/01/2025
Annual Revision	Throughout the policy, adalimumab-aacf was added as an example of an adalimumab product.	01/01/2026

	<p>Throughout the policy, it was specified that adalimumab-ryvk NDCs starting with 82009 are the Preferred product.</p> <p>For <b>Psoriatic Arthritis</b>, Otezla XR was added amongst the Step 1 Preferred Products. A trial of either or both Otezla products (Otezla and Otezla XR) collectively counts as one product.</p> <p>For <b>Psoriatic Arthritis</b>, Bimzelx was added as an agent that counts towards a trial of a Preferred Product.</p> <p><b>For Psoriatic Arthritis, Stelara subcutaneous was removed as a Preferred Product.</b></p>	
Selected Revision	<p><b>For Psoriatic Arthritis</b>, Xeljanz oral solution was added as a Step 2a agent. Criteria were updated to remove "tablets" from Xeljanz in the preferred products. Updated the Preferred and Non-Preferred Products table to include Bimzelx as a Step 2b agent. Cosentyx was added as an agent that also counts towards a trial of a Preferred Product.</p>	03/01/2026
Selected Revision	<p><b>For Psoriatic Arthritis:</b> Imuldosa subcutaneous (NDCs starting with 69448) was added as a Preferred ustekinumab subcutaneous product.</p>	04/15/2026
Selected Revision	<p><b>For Psoriatic Arthritis:</b> Sotyktu was added as a Step 1 Preferred Product.</p> <p><b>Avtozma SC:</b> For <b>Rheumatoid Arthritis</b> and <b>Juvenile Idiopathic Arthritis</b>, Avtozma was added as a Step 2a product.</p>	05/01/2026

The policy effective date is in force until updated or retired.

---

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2026 The Cigna Group.